newsGP - Unraveling diabetes and heart
News
DISPONSORS: New drugs and emerging strategies for risk profiling offer more options than ever before for managing CVD risk in people with diabetes.
The new Heart Foundation webinar will discuss the latest clinical developments on CVD among people with diabetes.
Cardiovascular disease (CVD) is the leading cause of death among people with diabetes, and about two thirds of cardiovascular deaths occur in people with diabetes or prediabetes in Australia.
People living with diabetes are up to four times more likely to have a heart attack or stroke, often considered to be at the same risk as someone who has previously had a heart attack or stroke.
The risk of CVD is higher in people with a longer history of diabetes, microvascular complications and poor glycemic control. The overall risk of death among people with type 2 diabetes was substantially higher in those younger than 55 years, even when glycemic targets were met.
Contemporary diabetes population-derived cardiovascular risk prediction equations, such as the New Zealand PREDICT equation, may be needed to better ascertain risk in an increasingly heterogeneous diabetes population.
To keep up with the latest developments, doctors can register for the new webinar on Thursday 28 July – Uncovering diabetes & heart: The latest strategies on risk & management – hosted by the Heart Foundation in partnership with the World Heart Federation and the Australian Diabetes Society.
Professor Rod Jackson, a professor of epidemiology at the University of Auckland and one of the architects of the CVD PREDICTION risk prediction equation, will present firsthand how CVD risk is stratified in the diabetes group. He will also explore how doctors can prioritize management for those at high risk.
Newer glucose-lowering agents have shown significant reductions in some of the most critical macrovascular complications among people with diabetes, including a reduction in ischemic events. Sodium-glucose co-transporter 2 (SGLT2) inhibitors also demonstrated a reduction in heart failure hospitalizations, CVD mortality, and progression of chronic kidney disease, regardless of the individual’s diabetes status.
To speak to the latest evidence on newer glucose-lowering agents, Professor Richard O’Brien, consultant endocrinologist at Private Hospital Reservoir and Dean of Clinical Medicine at the University of Melbourne, will provide a much-needed update on their diabetes and cardiovascular pharmacological therapies. benefit.
Based on the results of several important studies, many international guidelines now recommend SGLT2 inhibitors for people with symptomatic heart failure with reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. Associate Professor Ingrid Hopper, general practitioner and clinical pharmacologist at Alfred Health, will join us to discuss the role of SGLT2 inhibitors in the treatment of heart failure.
There to provide practical advice and commentary on the clinical application of the evidence are Dr Roy Rasalam, GP at Townsville Family Medical Center and co-authors Type 2 diabetes management: A handbook for general practice.
There will be opportunities to take part in interactive Q&A with expert panelists. Don’t miss it – this 60-minute session is the next in the Heart Foundation clinical webinar series, previously described by GPs as being of the ‘highest quality/intensity/efficiency’.
This webinar is accredited by the RACGP for 2 CPD points (activity no. 355838).
Sign up now.
Sign in below to join the conversation.
cardiovascular disease diabetes CPD Heart Foundation
newsGP weekly poll
How often do you provide mental health consultations?
#newsGP #Unraveling #diabetes #heart
Comments
Post a Comment